Much progress has been made in dealing with cancer, with one of the latest medical techniques using some of the most advanced technology. Tempus, the Chicago-based company established with the help by entrepreneur Eric Lefkofsky, is leading the way in the war on cancer with what is known as data-precision medical treatment.
One of the most important elements in treating cancer is learning how it develops in each person so afflicted, but understanding this issue will require a careful study of the patient’s personal records. This may involve the studying of records that are often in the form of scattered information or notes written by individual doctors. It was Tempus that developed software designed to recognize characters and thus decipher such information in an effective manner.
Another important advancement in cancer research involves the study of health anomalies at the smallest level, specifically in the cells and molecules that comprise the human body. Such studies are today possible through what is known as genome sequencing, or the examination of the genes that are the basis of living organisms. One previous drawback to such research had been its tremendous cost. However, the work of Tempus and other organizations have greatly reduced this expense to manageable levels. The principle of genome sequencing could eventually enable physicians to develop treatment strategies that are customized to individual patients, which can greatly increase the chance of a successful recovery. This philosophy could later be adopted to treat other ailments of health conditions.
Originally from Michigan, 48-year-old Eric Lefkofsky has spent much of his life in and around the Chicago area. A graduate of the University of Michigan, he earned his law degree from the institution in 1993. He is currently serving as an adjunct professor at the University of Chicago’s Booth School of Business.
Lefkofsky has been involved in the creation of several companies, including the e-commerce marketplace Groupon. Inadequacies in the availability of cancer data became a personal matter after his wife was diagnosed with the disease, which spurred the creation of Tempus. The benefits of the work being done by his company could extend to millions of others when considering that, at present rates, approximately 40 percent of American adults will eventually be diagnosed with some type of cancer.
Eric Lefkofsky’s Social Media: www.facebook.com/eplefkofsky/